# Stoke Therapeutics, Inc.: overview STOK · Nasdaq · CIK 1623526 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/stok.md) · [Financials](/companies/stok/financials.md) · [Filings](/companies/stok/filings.md) · [Insiders](/companies/stok/insiders.md) Latest reported revenue: [$9.3m](/filings/0001193125-26-330557.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 3, 2026 (XBRL us-gaap:Revenues, accession 0001193125-26-330557). ## Last eight quarters | Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [4.9](/filings/0001193125-25-264720.md) | [22.6 d](/filings/0001193125-26-108362.md) | [159](/filings/0001193125-26-211874.md) | [13.8](/filings/0001193125-26-330557.md) | [10.6](/filings/0001193125-25-264720.md) | [1.4 d](/filings/0001193125-26-108362.md) | [6.2](/filings/0001193125-26-211874.md) | [9.3](/filings/0001193125-26-330557.md) | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | [(613.1%)](/filings/0001193125-25-264720.md) | [(60.4%) d](/filings/0001193125-26-108362.md) | [70.2%](/filings/0001193125-26-211874.md) | [(197.6%)](/filings/0001193125-26-330557.md) | [(405.3%)](/filings/0001193125-25-264720.md) | [(4382.2%) d](/filings/0001193125-26-108362.md) | [(857.6%)](/filings/0001193125-26-211874.md) | [(701.7%)](/filings/0001193125-26-330557.md) | | Net margin | % | [(540.0%)](/filings/0001193125-25-264720.md) | [(46.4%) d](/filings/0001193125-26-108362.md) | [71.2%](/filings/0001193125-26-330557.md) | [(170.0%)](/filings/0001193125-26-330557.md) | [(360.7%)](/filings/0001193125-25-264720.md) | [(4132.2%) d](/filings/0001193125-26-108362.md) | [(802.7%)](/filings/0001193125-26-330557.md) | [(660.8%)](/filings/0001193125-26-330557.md) | | Diluted EPS | $ per share | [(0.47)](/filings/0001193125-25-264720.md) | not reported | [1.90](/filings/0001193125-26-211874.md) | [(0.40)](/filings/0001193125-26-330557.md) | [(0.65)](/filings/0001193125-25-264720.md) | not reported | [(0.79)](/filings/0001193125-26-211874.md) | [(0.93)](/filings/0001193125-26-330557.md) | | Free cash flow | $m | [(21.7) d](/filings/0001193125-25-264720.md) | [(23.2) d](/filings/0001193125-26-108362.md) | [132](/filings/0001193125-26-211874.md) | [(25.6) d](/filings/0001193125-26-330557.md) | [(30.5) d](/filings/0001193125-25-264720.md) | [(30.7) d](/filings/0001193125-26-108362.md) | [(60.9)](/filings/0001193125-26-211874.md) | [(58.6) d](/filings/0001193125-26-330557.md) | - Revenue. XBRL Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure. - Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. ## Last five fiscal years | Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | not reported | [12.4](/filings/0000950170-24-035912.md) | [8.8](/filings/0000950170-25-041170.md) | [36.6](/filings/0001193125-26-108362.md) | [184](/filings/0001193125-26-108362.md) | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | not reported | [(841.2%)](/filings/0000950170-24-035912.md) | [(1307.2%)](/filings/0000950170-25-041170.md) | [(277.3%)](/filings/0001193125-26-108362.md) | [(11.2%)](/filings/0001193125-26-108362.md) | | Net margin | % | not reported | [(814.7%)](/filings/0000950170-24-035912.md) | [(1192.5%)](/filings/0000950170-25-041170.md) | [(243.4%)](/filings/0001193125-26-108362.md) | [(3.7%)](/filings/0001193125-26-108362.md) | | Diluted EPS | $ per share | [(2.34)](/filings/0001564590-23-003175.md) | [(2.60)](/filings/0000950170-24-035912.md) | [(2.38)](/filings/0000950170-25-041170.md) | [(1.65)](/filings/0001193125-26-108362.md) | [(0.12)](/filings/0001193125-26-108362.md) | | Free cash flow | $m | [(68.1)](/filings/0001564590-23-003175.md) | [(35.8)](/filings/0000950170-24-035912.md) | [(82.7)](/filings/0000950170-25-041170.md) | [(87.1)](/filings/0001193125-26-108362.md) | [44.9](/filings/0001193125-26-108362.md) | - Revenue. XBRL Revenue: us-gaap:Revenues. - Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:Revenues. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:Revenues. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:Revenues. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/stok/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $192.3m | 5,877,357 | | Added +491,643 | | [RTW INVESTMENTS, LP](/funds/1493215.md) | 2026-06-30 | $184.0m | 5,623,525 | | Unchanged | | [FMR LLC](/funds/315066.md) | 2026-06-30 | $173.8m | 5,313,100 | | Reduced −70,566 | | [Lynx1 Capital Management LP](/funds/1910456.md) | 2026-06-30 | $132.1m | 4,038,404 | | Reduced −725,269 | | [Redmile Group, LLC](/funds/1425738.md) | 2026-06-30 | $129.1m | 3,945,920 | | Reduced −218,200 | | [WELLINGTON MANAGEMENT GROUP LLP](/funds/902219.md) | 2026-06-30 | $115.2m | 3,519,301 | | Added +423,601 | | [MORGAN STANLEY](/funds/895421.md) | 2026-06-30 | $113.0m | 3,452,795 | | Added +29,515 | | [BAKER BROS. ADVISORS LP](/funds/1263508.md) | 2026-06-30 | $109.2m | 3,336,697 | | Unchanged | | [TORONTO DOMINION BANK](/funds/947263.md) | 2026-06-30 | $103.8m | 3,173,258 | | Unchanged | | [STATE STREET CORP](/funds/93751.md) | 2026-06-30 | $93.3m | 2,852,240 | | Added +575,728 | ## Recent filings [All 621 filings](/companies/stok/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-10-29 | 16:05 ET | [8-K](/filings/0001193125-26-437775.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-437775 | | 2026-09-25 | 16:05 ET | [8-K](/filings/0001193125-26-402820.md) | 5.02 Departure or appointment of officers or directors | 0001193125-26-402820 | | 2026-08-03 | 17:06 ET | [8-K](/filings/0001193125-26-330804.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-330804 | | 2026-08-03 | 16:07 ET | [10-Q](/filings/0001193125-26-330557.md) | Quarterly report, period 2026-06-30 | 0001193125-26-330557 | | 2026-08-03 | 16:05 ET | [8-K](/filings/0001193125-26-330537.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-330537 | | 2026-06-30 | 08:02 ET | [8-K](/filings/0001193125-26-289409.md) | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-289409 | | 2026-06-04 | 16:08 ET | [8-K](/filings/0001193125-26-257394.md) | 5.07 Shareholder vote results | 0001193125-26-257394 | | 2026-05-07 | 16:19 ET | [8-K](/filings/0001193125-26-212020.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-212020 | | 2026-05-07 | 16:06 ET | [10-Q](/filings/0001193125-26-211874.md) | Quarterly report, period 2026-03-31 | 0001193125-26-211874 | | 2026-04-22 | 16:05 ET | [DEF 14A](/filings/0001193125-26-170362.md) | Proxy statement, period 2026-06-03 | 0001193125-26-170362 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001193125-26-108362.md), filed Mar 16, 2026. ## Forecast league Q3 FY2026, the quarter ended 2026-09-30, locked when the 8-K was accepted. It is scored when the 10-Q or 10-K is ingested. [See the target](/leagues/2026q3/targets/130bf7e3-5603-4a78-8722-0d89dcee3c8d) ## About the filer - CIK: 1623526 - Tickers: STOK - Exchange: Nasdaq - SIC code: 2834 Pharmaceutical Preparations - State of incorporation: DE - Filer category: Non-accelerated filer
Smaller reporting company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 29, 2026, 16:06 ET. No prices; not investment advice.